Aclarion (ACON) announced the first patient enrollment in the Clarity trial evaluating Nociscan’s clinical and economic value in spine surgery. The first patient was enrolled at the Texas Back Institute. The company reaffirms internal interim results of Clarity expected in Q2 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACON:
- Aclarion to present NOCISCAN at State of Spine Surgery Think Tank
- Aclarion adds UHealth, University of Miami as trial site for Nociscan
- Aclarion announces Texas Back Insitute as new CLARITY trial site
- Aclarion announces agreement with the Spine Institute of Louisiana
- Aclarion files $150M mixed securities shelf